Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center

被引:2
作者
Dogan, Barut [1 ]
Sema, Yildirim Arslan [2 ]
Bora, Kunay [1 ]
Veysel, Umman [3 ]
Benan, Dernek [4 ]
Ezgi, Kiran Tasci [5 ]
Gozde, Akkus Kayali [6 ]
Demir, Derya [7 ]
Ozsan, Nazan [7 ]
Hekimgil, Mine [7 ]
Zumrut, Sahbudak Bal [2 ]
Miray, Karakoyun [1 ]
Funda, Cetin [1 ]
Sema, Aydogdu [1 ]
机构
[1] Ege Univ, Dept Pediat, Div Gastroenterol Hepatol & Nutr Dis, Med Sch, Izmir, Turkiye
[2] Ege Univ, Dept Pediat, Div Infect Dis, Med Sch, TR-35100 Izmir, Turkiye
[3] Ege Univ, Dept Gen Surg, Med Sch, I?zmir, Turkiye
[4] Ege Univ, Dept Pediat, Med Sch, Izmir, Turkiye
[5] Sivas Numune Hosp, Dept Pediat, Gastroenterol Hepatol & Nutr Dis, Sivas, Turkiye
[6] Ege Univ, Med Sch, Dept Microbiol, Izmir, Turkiye
[7] Ege Univ, Med Sch, Dept Pathol, Ege, Turkiye
关键词
Epstein-Barr virus; pediatric liver transplantation; post-transplant lymphoproliferative disorder; SOLID-ORGAN TRANSPLANTATION; RISK-FACTORS; DISEASE; IMMUNOSUPPRESSION; INFECTION; RECIPIENTS; THERAPY; VIREMIA; IMPACT; DONOR;
D O I
10.1002/jmv.29767
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The most prevalent malignancy that complicates both adult and pediatric solid organ transplantation is post-transplant lymphoproliferative disorder (PTLD). This study aimed to analyze the clinical and pathological characteristics, treatments, and outcomes of Epstein-Barr virus (EBV) DNAemia and PTLD in pediatric liver transplant recipients. A retrospective chart review was performed on 112 patients less than 18 years of age who underwent isolated orthotopic liver transplantation (OLT) between 2010 and 2022 at Ege University Children's Hospital. Data gathered for 1-year post-OLT included age at OLT, EBV, immunoglobulin (Ig)M/IgG status of the donor and recipient, indication for OLT, induction regimen, all immunosuppression levels, date and result of EBV polymerase chain reaction testing, rejection episodes documented by liver biopsy, and the development of PTLD. Forty-nine patients (43.75%) developed EBV DNAemia (median interval from surgery: 2 months, min-max: 2-36), of which 43 (87.8%) grafts came from living donors, and 6 (12.2%) came from deceased donors. Nine (18.4%) patients died during follow-up, and eight (16.3%) developed PTLD. Of these 8 patients; five patients developed EBV-related disease, one child developed hemophagocytic lymphohistiocytosis, one developed aplastic anemia, and one child developed B cell lymphoma. When PTLD patients and without-PTLD patients were compared, pediatric intensive care unit hospitalization, abnormal bone marrow biopsy findings, lymphadenopathy, age at diagnosis of EBV DNAemia, EBV viral load, tacrolimus (FK 506) pre-infection, were higher and tacrolimus 1-month levels were lower in patients with PTLD (p < 0.05). In logistic regression analysis, we showed that the age at diagnosis of EBV DNAemia was significantly higher in children with PTLD (p = 0.045; OR: 1.389; 95% CI: 1.007-1.914). PTLD is a rare but severe complication associated with EBV after OLT. This study demonstrated that PTLD is associated with older age, higher tacrolimus blood levels before EBV DNAemia, and higher peak EBV viral load at 1 month of EBV DNAemia.
引用
收藏
页数:12
相关论文
共 49 条
[1]   Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies [J].
Al-Mansour, Zeina ;
Nelson, Beverly P. ;
Evens, Andrew M. .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (03) :173-183
[2]   Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice [J].
Allen, Upton D. ;
Preiksaitis, Jutta K. .
CLINICAL TRANSPLANTATION, 2019, 33 (09)
[3]  
American Society of Transplantation Infectious Diseases Community of Practice (AST-IDCOP), Guidelines for the Prevention and Management of Infectious Complications of Solid Organ Transplantation
[4]   Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients [J].
Cacciarelli, TV ;
Reyes, J ;
Jaffe, R ;
Mazariegos, GV ;
Jain, A ;
Fung, JJ ;
Green, M .
PEDIATRIC TRANSPLANTATION, 2001, 5 (05) :359-364
[5]   Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression [J].
Caillard, S ;
Dharnidharka, V ;
Agodoa, L ;
Bohen, E ;
Abbott, K .
TRANSPLANTATION, 2005, 80 (09) :1233-1243
[6]  
Cao S, 1999, Pediatr Transplant, V3, P22, DOI 10.1034/j.1399-3046.1999.00002.x
[7]   Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation [J].
Chen, Ho-Sheng ;
Ho, Ming-Chih ;
Hu, Rey-Heng ;
Wu, Jia-Feng ;
Chen, Huey-Ling ;
Ni, Yen-Hsuan ;
Hsu, Hong-Yuan ;
Jeng, Yung-Ming ;
Chang, Mei-Hwei .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (09) :1362-1368
[8]  
Cockfield S M, 2001, Transpl Infect Dis, V3, P70
[9]  
COX KL, 1995, TRANSPLANTATION, V59, P524
[10]   Post-transplant lymphoproliferative disease [J].
Dharnidharka, Vikas R. ;
Araya, Carlos E. .
PEDIATRIC NEPHROLOGY, 2009, 24 (04) :731-736